Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 37,414
  • Shares Outstanding, K 33,113
  • Annual Sales, $ 9,900 K
  • Annual Income, $ -53,320 K
  • 36-Month Beta 2.05
  • Price/Sales 3.29
  • Price/Cash Flow N/A
  • Price/Book 47.97

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.99 +10.10%
on 02/14/19
1.45 -24.83%
on 01/24/19
+0.02 (+1.87%)
since 01/22/19
3-Month
0.60 +81.67%
on 12/11/18
1.45 -24.83%
on 01/24/19
-0.19 (-14.84%)
since 11/21/18
52-Week
0.60 +81.67%
on 12/11/18
5.20 -79.04%
on 03/12/18
-1.41 (-56.40%)
since 02/22/18

Most Recent Stories

More News
Curis, Inc. to Present at the 2019 BIO CEO & Investor Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive...

CRIS : 1.09 (-3.54%)
Has Curis (CRIS) Outpaced Other Medical Stocks This Year?

Is (CRIS) Outperforming Other Medical Stocks This Year?

CRIS : 1.09 (-3.54%)
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?

Is (CRIS) Outperforming Other Medical Stocks This Year?

CRIS : 1.09 (-3.54%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2019, the independent Compensation...

CRIS : 1.09 (-3.54%)
Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session

Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

CRIS : 1.09 (-3.54%)
ADRO : 4.09 (+0.25%)
Analysis: Positioning to Benefit within Dicerna Pharmaceuticals, Sun Life Financial, Autodesk, Eagle Pharmaceuticals, Curis, and Accenture -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dicerna Pharmaceuticals, Inc....

DRNA : 10.51 (-2.14%)
ADSK : 161.51 (+1.05%)
CRIS : 1.09 (-3.54%)
EGRX : 46.23 (+2.19%)
SLF : 37.81 (+0.59%)
ACN : 161.50 (+1.23%)
Curis to Present at the 60th Annual Meeting of the American Society of Hematology

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations...

CRIS : 1.09 (-3.54%)
Curis to Present at 33rd Society for Immunotherapy of Cancer Annual Meeting and Cowen IO NEXT Summit

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced upcoming presentations at the...

CRIS : 1.09 (-3.54%)
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 1.09 (-3.54%)
Curis: 3Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $7.2 million in its third quarter.

CRIS : 1.09 (-3.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade CRIS with:

Business Summary

Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis' product development involves the use of small molecules or proteins to modulate...

See More

Key Turning Points

2nd Resistance Point 1.17
1st Resistance Point 1.13
Last Price 1.09
1st Support Level 1.06
2nd Support Level 1.03

See More

52-Week High 5.20
Fibonacci 61.8% 3.44
Fibonacci 50% 2.90
Fibonacci 38.2% 2.36
Last Price 1.09
52-Week Low 0.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar